MedTrace Logo

Evaluation of Pupillometry for cyp2d6 Phenotyping in Children Treated With Tramadol

NCT03052218 · Status: TERMINATED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 50

Last updated 2022-11-30

No results posted yet for this study

Summary

Pupillometry will be performed before administration of tramadol, at T0 and then 1 to twice per hour in children having received tramadol as a pain killer as part of his/her routine care.

Pupillometry measurement will be correlate to CYP2D6 phenotype and CYP2D6 genetic score

Conditions

  • Drug Intolerance
  • Cytochrome P450 CYP2D6 Enzyme Deficiency
  • Drug Effect

Interventions

DEVICE

Pupillometry

Pupillometry performed before administration of tramadol, at T0 and then 1 to twice per hour, during the stay of the patient in the emergency department

Sponsors & Collaborators

  • University Hospital, Geneva

    lead OTHER

Principal Investigators

  • Frederique j Rodieux, MD · Division of Clinical Pharmacology and Toxicology Geneva University Hospitals, Geneva, Switzerland

Study Design

Allocation
NA
Purpose
DEVICE_FEASIBILITY
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
1 Year
Max Age
15 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-03-01
Primary Completion
2022-06-30
Completion
2022-06-30

Countries

  • Switzerland

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03052218 on ClinicalTrials.gov